Perspective

Perspective Roundtable

Screening for Prostate Cancer

Thomas H. Lee, M.D., Philip W. Kantoff, M.D., and Mary F. McNaughton-Collins, M.D., M.P.H.

N Engl J Med 2009; 360:e18March 26, 2009

Video

• Download a Transcript of Video (PDF)

Poll Results

Contributors

In two large randomized trials, researchers examined the effect of annual prostate-specific–antigen (PSA) screening on the rate of death from prostate cancer and found that it was small and was offset by false positive diagnoses. Since screening may have benefits in catching cancers early but may also carry risks including that of unnecessary treatment, professional societies have split on the question of whether to recommend regular PSA screening. In a roundtable discussion moderated by Dr. Thomas Lee, oncologist Philip Kantoff and primary care physician Mary McNaughton-Collins debate the clinical implications of the new findings and the best way to advise patients about undergoing PSA testing. Should these studies change practice? Watch the video, participate in the poll, and contribute your thoughts at NEJM.org. Polling and commenting close April 1, 2009.

• Download Readers’ Comments (PDF)

Citing Articles (3)

Citing Articles

1. 1

   M. Cortesi, E. Fridman, A. Volkov, S. Sh. Shilstein, R. Chechik, A. Breskin, D. Vartsky, G. Raviv, J. Ramon. (2010) New prospective for non-invasive detection, grading, size evaluation, and tumor location of prostate cancer. The Prostate 70:15, 1701-1708
   CrossRef

2. 2

   Yongliang Yang, S James Adelstein, Amin I Kassis. (2010) Putative molecular signatures for the imaging of prostate cancer. Expert Review of Molecular Diagnostics 10:1, 65-74
   CrossRef

3. 3

   Jeremy A Squire. (2009) TMPRSS2-ERG and PTEN loss in prostate cancer. Nature Genetics 41:5, 509-510
   CrossRef